Relief Therapeutics Holding AG (RLF) - Net Assets
Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has net assets worth CHF32.63 Million CHF (≈ $41.26 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF47.99 Million ≈ $60.67 Million USD) and total liabilities (CHF15.35 Million ≈ $19.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RLF asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF32.63 Million |
| % of Total Assets | 68.0% |
| Annual Growth Rate | -3.22% |
| 5-Year Change | -45.31% |
| 10-Year Change | 107.65% |
| Growth Volatility | 193.5 |
Relief Therapeutics Holding AG - Net Assets Trend (2006–2024)
This chart illustrates how Relief Therapeutics Holding AG's net assets have evolved over time, based on quarterly financial data. Also explore RLF current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Relief Therapeutics Holding AG (2006–2024)
The table below shows the annual net assets of Relief Therapeutics Holding AG from 2006 to 2024. For live valuation and market cap data, see RLF stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF36.66 Million ≈ $46.35 Million |
-29.80% |
| 2023-12-31 | CHF52.23 Million ≈ $66.03 Million |
-64.08% |
| 2022-12-31 | CHF145.42 Million ≈ $183.85 Million |
-19.89% |
| 2021-12-31 | CHF181.53 Million ≈ $229.50 Million |
+170.77% |
| 2020-12-31 | CHF67.04 Million ≈ $84.76 Million |
+368.90% |
| 2019-12-31 | CHF14.30 Million ≈ $18.08 Million |
-32.82% |
| 2018-12-31 | CHF21.28 Million ≈ $26.91 Million |
+1.61% |
| 2017-12-31 | CHF20.95 Million ≈ $26.48 Million |
-5.81% |
| 2016-12-31 | CHF22.24 Million ≈ $28.11 Million |
+25.93% |
| 2015-12-31 | CHF17.66 Million ≈ $22.32 Million |
-32.99% |
| 2014-12-31 | CHF26.35 Million ≈ $33.31 Million |
+27.82% |
| 2013-12-31 | CHF20.61 Million ≈ $26.06 Million |
+867.35% |
| 2012-12-31 | CHF-2.69 Million ≈ $-3.40 Million |
-678.91% |
| 2011-12-31 | CHF464.04K ≈ $586.67K |
-99.11% |
| 2010-12-31 | CHF52.38 Million ≈ $66.22 Million |
-7.68% |
| 2009-12-31 | CHF56.73 Million ≈ $71.73 Million |
-17.70% |
| 2008-12-31 | CHF68.94 Million ≈ $87.15 Million |
+6.88% |
| 2007-12-31 | CHF64.50 Million ≈ $81.54 Million |
-2.48% |
| 2006-12-31 | CHF66.13 Million ≈ $83.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Relief Therapeutics Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22050766700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF1.40 Million | 3.83% |
| Other Comprehensive Income | CHF756.00K | 2.06% |
| Other Components | CHF270.25 Million | 737.09% |
| Total Equity | CHF36.66 Million | 100.00% |
Relief Therapeutics Holding AG Competitors by Market Cap
The table below lists competitors of Relief Therapeutics Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eurospan Holdings Bhd
KLSE:7094
|
$36.36 Million |
|
Midland Exploration Inc
V:MD
|
$36.37 Million |
|
Intercure
TA:INCR
|
$36.39 Million |
|
Vext Science Inc
F:VV5
|
$36.39 Million |
|
Dacome International Ltd
TWO:9960
|
$36.30 Million |
|
Urbanise.com Ltd
AU:UBN
|
$36.29 Million |
|
Milux Corporation Bhd
KLSE:7935
|
$36.29 Million |
|
Biohit Oyj B
HE:BIOBV
|
$36.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relief Therapeutics Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 52,228,000 to 36,664,000, a change of -15,564,000 (-29.8%).
- Net loss of 17,119,000 reduced equity.
- Other comprehensive income decreased equity by 5,394,000.
- Other factors increased equity by 6,949,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-17.12 Million | -46.69% |
| Other Comprehensive Income | CHF-5.39 Million | -14.71% |
| Other Changes | CHF6.95 Million | +18.95% |
| Total Change | CHF- | -29.80% |
Book Value vs Market Value Analysis
This analysis compares Relief Therapeutics Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CHF396.38 | CHF2.89 | x |
| 2007-12-31 | CHF247.31 | CHF2.89 | x |
| 2008-12-31 | CHF413.17 | CHF2.89 | x |
| 2009-12-31 | CHF41.90 | CHF2.89 | x |
| 2010-12-31 | CHF315.04 | CHF2.89 | x |
| 2011-12-31 | CHF2.69 | CHF2.89 | x |
| 2012-12-31 | CHF-15.41 | CHF2.89 | x |
| 2013-12-31 | CHF47.04 | CHF2.89 | x |
| 2014-12-31 | CHF22.19 | CHF2.89 | x |
| 2015-12-31 | CHF12.04 | CHF2.89 | x |
| 2016-12-31 | CHF7.03 | CHF2.89 | x |
| 2017-12-31 | CHF4.21 | CHF2.89 | x |
| 2018-12-31 | CHF4.15 | CHF2.89 | x |
| 2019-12-31 | CHF2.72 | CHF2.89 | x |
| 2020-12-31 | CHF11.11 | CHF2.89 | x |
| 2021-12-31 | CHF20.21 | CHF2.89 | x |
| 2022-12-31 | CHF13.76 | CHF2.89 | x |
| 2023-12-31 | CHF4.44 | CHF2.89 | x |
| 2024-12-31 | CHF2.92 | CHF2.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relief Therapeutics Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.39%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.45x
- Recent ROE (-46.69%) is above the historical average (-707.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -10.92% | -291.33% | 0.03x | 1.16x | CHF-13.84 Million |
| 2007 | -3.10% | -13.49% | 0.19x | 1.23x | CHF-8.45 Million |
| 2008 | -13.64% | -64.63% | 0.19x | 1.11x | CHF-16.29 Million |
| 2009 | -21.53% | -88.89% | 0.21x | 1.15x | CHF-17.89 Million |
| 2010 | -37.03% | -5020.16% | 0.01x | 1.11x | CHF-24.63 Million |
| 2011 | -12750.17% | 0.00% | 0.00x | 7.06x | CHF-59.21 Million |
| 2012 | 0.00% | -3.71% | 27.13x | 0.00x | CHF-1.03 Million |
| 2013 | -60.73% | -59.09% | 0.45x | 2.28x | CHF-14.25 Million |
| 2014 | -47.04% | -63.63% | 0.47x | 1.58x | CHF-15.04 Million |
| 2015 | -51.84% | -3574.15% | 0.01x | 1.71x | CHF-10.92 Million |
| 2016 | -75.71% | -112226.67% | 0.00x | 1.41x | CHF-19.06 Million |
| 2017 | -13.78% | 0.00% | 0.00x | 1.48x | CHF-4.98 Million |
| 2018 | -2.05% | -76.90% | 0.02x | 1.67x | CHF-2.56 Million |
| 2019 | -52.18% | 0.00% | 0.00x | 1.39x | CHF-8.89 Million |
| 2020 | -11.68% | 0.00% | 0.00x | 1.16x | CHF-14.53 Million |
| 2021 | -19.12% | -1045.02% | 0.01x | 1.39x | CHF-52.86 Million |
| 2022 | -34.93% | -835.22% | 0.03x | 1.30x | CHF-65.33 Million |
| 2023 | -187.99% | -1627.40% | 0.08x | 1.46x | CHF-103.40 Million |
| 2024 | -46.69% | -203.39% | 0.16x | 1.45x | CHF-20.79 Million |
Industry Comparison
This section compares Relief Therapeutics Holding AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,238,779
- Average return on equity (ROE) among peers: -33.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relief Therapeutics Holding AG (RLF) | CHF32.63 Million | -10.92% | 0.47x | $36.33 Million |
| Addex Therapeutics Ltd (ADXN) | $33.84 Million | -92.04% | 0.29x | $7.10 Million |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $2.25 Billion |
| Basilea Pharmaceutica AG (BSLN) | $125.38 Million | -47.04% | 0.20x | $699.48 Million |
| Evolva Holding SA (EVE) | $21.86 Million | -39.62% | 1.03x | $7.08 Million |
| Idorsia Ltd (IDIA) | $-1.21 Billion | 0.00% | 0.00x | $759.27 Million |
| Molecular Partners AG (MOLN) | $135.79 Million | -13.71% | 0.36x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $29.28 Million | -80.19% | 0.42x | $360.88 Million |
| Santhera Pharmaceuticals Holding AG (SANN) | $104.47 Million | -42.74% | 0.08x | $244.59 Million |
| Xlife Sciences AG (XLS) | $235.23 Million | 6.08% | 1.08x | $122.27 Million |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more